(1S,3′S)-Solifenacin succinate is a pharmaceutical compound primarily used as an antimuscarinic agent for the treatment of overactive bladder. It functions by selectively inhibiting the M3 muscarinic acetylcholine receptors, which are responsible for bladder contraction, thereby reducing urinary urgency and frequency. The compound is characterized by its chiral centers, which contribute to its specific pharmacological activity. Solifenacin succinate is typically administered in its succinate salt form, enhancing its solubility and bioavailability. The substance exhibits a favorable pharmacokinetic profile, including a relatively long half-life, allowing for once-daily dosing. Common side effects may include dry mouth, constipation, and blurred vision, which are typical of anticholinergic medications. Its chemical structure includes a bicyclic moiety, which is essential for its receptor binding affinity. Overall, (1S,3′S)-Solifenacin succinate represents a significant advancement in the management of urinary disorders, providing symptomatic relief for patients with overactive bladder syndrome.

(1S,3′S)-Solifenacin succinate

862207-71-4: Butanedioic acid, compd. with (3S)-1-azabicyclo[2.2.2]oct-3-yl (1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1), (1S,3′S)-Solifenacin succinate

Solifenacin EP Impurity H Succinate

Please enquire for more information about (1S,3’S)-Solifenacin succinate including the price, delivery time and more detailed product information at the technical inquiry form on this page

CAS 862207-71-4: (1S,3′S)-Solifenacin succinate

Solifenacin EP Impurity H Succinate

Ref: 4Z-S-1813

(1S,3’S)-Solifenacin succinate

Ref: 3D-FS167460

Solifenacin EP Impurity H-d5 Succinate

Ref: 4Z-S-1859